Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Gruppo Oncologico del Nord-Ovest
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05845450CT.gov Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | — | Recruiting | — | — | — |
NCT05382741CT.gov Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial | — | Unknown | — | — | — |
NCT06680739CT.gov Single cEll pRofiling PErsistaNce To ImmuNothErapy | — | Recruiting | — | — | — |
NCT05187338CT.gov Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04696848CT.gov The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | — | Terminated | — | — | — |
NCT04108481CT.gov Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT04145193CT.gov Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | — | Withdrawn | — | — | — |
NCT03982173CT.gov Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | — | Withdrawn | — | — | — |
NCT04068610CT.gov COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | — | Active Not Recruiting | — | — | — |
NCT03802747CT.gov Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | — | Withdrawn | — | — | — |
Show 20 more trialsShow fewer
NCT03851614CT.gov Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03101475CT.gov Synergism of Immunomodulation and Tumor Ablation | — | Completed | — | — | — |
NCT03539822CT.gov Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | — | Recruiting | — | — | — |
NCT03376659CT.gov Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03435107CT.gov Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03428126CT.gov Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | — | Completed | — | — | — |
NCT03206073CT.gov A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | — | Completed | — | — | — |
NCT02963831CT.gov A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | — | Completed | — | — | — |
NCT02888743CT.gov Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03005002CT.gov Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | — | Completed | — | — | — |
NCT03122509CT.gov A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | — | Completed | — | — | — |
NCT02983578CT.gov Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT02870920CT.gov Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT02669914CT.gov MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | — | Terminated | — | — | — |
NCT02754856CT.gov Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT02777710CT.gov Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers | — | Completed | — | — | — |
NCT02586987CT.gov A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | — | Completed | — | — | — |
NCT02227667CT.gov Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT01975831CT.gov A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Gruppo Oncologico del Nord-Ovest | P2 | B · 61 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →